person · Reporting owner

Jung Melita Sun

Disclosed activity across 2 companies

Tapewire entity: 83665
SEC CIK: 0001962407

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Structure Therapeutics Inc.GPCR · Entity 1222	Chief Business Officer	February 07, 2023	February 10, 2023
Terns Pharmaceuticals, Inc.TERN · Entity 49595	Chief Business Officer	January 30, 2025	February 04, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Structure Therapeutics Inc.

Report date February 07, 2023 · Filed February 10, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
American Depositary SharesSEC Table II · derivative / convertible security	Direct	1,000	Reported balance After 2023-02-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-07 · Purchase · Acquired 1,000 · Balance 1,000 F1: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F2: The American Depositary Shares were purchased in the Issuer's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.

F2: The American Depositary Shares were purchased in the Issuer's initial public offering.

Terns Pharmaceuticals, Inc.

Report date January 30, 2025 · Filed February 04, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,250	Reported balance After 2024-11-30 transaction · row 1 1 source row Row 1 · 2024-11-30 · Purchase · Acquired 2,250 · Balance 2,250 F1: Includes 2,250 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2035-01-29	Direct	325,000	Reported balance After 2025-01-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-30 · Grant · Acquired 325,000 · Balance 325,000 F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 2,250 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024.

F2: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 30, 2025 Filed Feb 4, 2025 00:28 UTC	Terns Pharmaceuticals, Inc. TERN · Entity 49595	GrantStock Option (Right to Buy) · Derivative	325,000	$0.00 Strike: $4.64	$0.00	Disclosure SEC source: 0001562180-25-000853 · primarydocument.xml · derivative · entry 2 Jung Melita Sun · CIK 0001962407 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2035-01-29 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document
November 30, 2024 Filed Feb 4, 2025 00:28 UTC	Terns Pharmaceuticals, Inc. TERN · Entity 49595	PurchaseCommon Stock	2,250	$5.11	$11,497.50	Disclosure SEC source: 0001562180-25-000853 · primarydocument.xml · nonDerivative · entry 1 Jung Melita Sun · CIK 0001962407 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 F1 · shares: Includes 2,250 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024. Read SEC document
May 01, 2024 Filed May 2, 2024 21:29 UTC	Terns Pharmaceuticals, Inc. TERN · Entity 49595	GrantStock Option (Right to buy) · Derivative	475,000	$0.00 Strike: $5.08	$0.00	Disclosure SEC source: 0001562180-24-003735 · primarydocument.xml · derivative · entry 1 Jung Melita Sun · CIK 0001962407 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document
February 07, 2023 Filed Feb 10, 2023 00:06 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	PurchaseAmerican Depositary Shares · Derivative	1,000	$15.00	$15,000.00	Disclosure SEC source: 0001209191-23-008164 · doc4.xml · derivative · entry 1 Jung Melita Sun · CIK 0001962407 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F2 · kind: The American Depositary Shares were purchased in the Issuer's initial public offering. F1 · derivative.exercise_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F1 · derivative.expiration_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.